Idiopathic calcinosis cutis of the penis
2 Smllli I'R. UroL'kliursl K). tVlluliir bluL' IIL'\US OI Ihf scltTii. Anh OphilmhiH'! l'»7(.; 94: fil8-2(l. 3 FuU'I I>S, i!hiit;;iviin HS, Bluciicvu.s cii'lhc ulLTLii£.'(.L'rvLX. Hum I'atlwl 19SS: If): 7*J-Sfi. 4 Hasson A. (.luticrrcz \iC. Mcinn LcI ii/. Biuo iiLni on llic prcpuLXand glaniLs penis. .S'iiiii Odiccr 1990; S: 15-19. 5 Zaiiis N. T/ii' .Wii/ in livulth itiid Disfitsc. 2m\ t'tlri. Norwalk. CV: Applcton J4 LHnge. 1990.
Intracorporeal calcifications after self-injection of papaverine.
Penile indurations were found at follow-up examination in six of 120 patients with erectile dysfunction who practice intracavernosal self-injection of papaverine-phentolamine. In four of these six, cavernosal calcifications were demonstrated by means of ultrasound (US) and radiography. Most of the calcifications were close to the site of injection, but some were more distant. Cavernosal calcifications must be considered a possible complication of self-injection of papaverine-phentolamine. Baseline US and radiographic studies of the penis are advisable before starting treatment.
Pharmacokinetics and Metabolism of 14C-Brivaracetam, a Novel SV2A Ligand, in Healthy Subjects
This study was designed to investigate the human absorption, disposition, and mass balance of 14C-brivaracetam, a novel high affinity SV2A ligand with potent anticonvulsant activity. Six healthy male subjects received a single p.o. dose of 14C-brivaracetam (150 mg, 82 μCi, or 3.03 MBq). Serial blood and complete urine and feces were collected until 144 h postdose. Expired air samples were obtained until 24 h. Brivaracetam was rapidly absorbed, with Cmax of 4 μg/ml occurring within 1.5 h of dosing. Unchanged brivaracetam amounted to 90% of the total plasma radioactivity, suggesting a modest first-pass effect. Plasma protein binding of radioactivity was low (17.5%). Urinary excretion exceeded 90% after 2 days, and the final mass balance reached 96.8% of the radioactivity in urine and 0.7% in feces. Only 8.6% of the radioactive dose was recovered in urine as unchanged brivaracetam, the remainder being identified as non–cytochrome P450 (P450)- and P450-dependent biotransformation products resulting from hydrolysis of the amide moiety (M9, 34.2%), hydroxylation of the n-propyl side chain (M1b, 15.9%), and a combination of these two pathways leading to the hydroxy acid (M4b, 15.2%). Minor amounts of taurine and glucuronic acid conjugates and other oxidized derivatives were also identified. Brivaracetam is completely absorbed, is weakly bound to plasma proteins, extensively biotransformed through several metabolic pathways, and eliminated renally.